Biocompatible fungal chitosan encapsulated phytogenic silver nanoparticles enhanced antidiabetic, antioxidant and antibacterial activity.

The work synthesized the fungal chitosan (FCS) encapsulated Gynura procumbens (GP) mediated silver nanoparticles (GP-AgNPs) for enhanced antidiabetic, antioxidant and antibacterial activity. The FCS-GP-AgNPs were characterized through UV-Visible spectroscopy, FTIR, XRD, Zeta size analyzer and TEM. The FTIR spectrum of GP-AgNPs exhibited functional groups of phenolic and flavonoids. The crystal peaks related to silver and chitosan in FCS-GP-AgNPs were demonstrated by XRD spectrum. The polydispersed nanoparticles such as AgNPs and FCS-GP-AgNPs were observed with size <100 nm by TEM. Zeta potential size analyzer indicated the average size and zeta potential of GP-AgNPs were 78.37 nm and -32.9 mV, whereas FCS-GP-AgNPs had 53.6 mV and 79.65 nm respectively. The FCS-GP-AgNPs was inhibited the α-glucosidase and α-amylase at 3.6 and 7.5 μg/mL respectively. Furthermore, FCS-GP-AgNPs were showed minimal inhibitory concentration (MIC) for Bacillus cereus (8.12 ± 0.12 μg/mL), Staphylococcus aureus (4.08 ± 0.47 μg/mL), Listeria monocytogenes (4.95 ± 0.32 μg/mL), Escherichia coli (8.25 ± 0.18 μg/mL), and Salmonella enterica (4.12 ± 0.64 μg/mL). In addition, the biocompatibility of FCS-GP-AgNPs was tested in A549, LN229, and NIH3T3 cells. This work concluded that FCS-GP-AgNPs proved to be biocompatible in terms of less cytotoxicity and promising in antibacterial and diabetics related enzyme inhibitory activity.